Abstract
Background
The efficacy and potential toxicity of rechallenge with combination ipilimumab and nivolumab has not been described. Retreatment of patients with immune checkpoint inhibitors in the setting of prior significant toxicity lacks evidence-based guidance.
Methods
We present the first three, consecutive patients who received re-treatment with combination ipilimumab and nivolumab for metastatic melanoma managed at our institution.
Results
Rechallenge with combination ipilimumab and nivolumab in the setting of prior grade 3 toxicity with initial combination therapy is feasible, and responses are seen. We highlight the fact that grade 3 toxicity is likely to recur, but if so, can be manageable.
Conclusions
Retreatment with ipi + nivo may be considered an option in carefully selected, well-informed patients. More research is required to delineate the benefits and risks with this approach.
Similar content being viewed by others
Abbreviations
- ALT:
-
Alanine aminotransferase
- CT:
-
Computed tomography
- ECOG:
-
Eastern Co-operative Group
- FDG:
-
2-Fluoro-2-deoxy-d-glucose
- Ipi + nivo:
-
Ipilimumab and nivolumab
- irAE:
-
Immune-related adverse event
- MMF:
-
Mycophenolate mofetil
- MRI:
-
Magnetic resonance imaging
- PET-CT:
-
Positron emission tomography-computed tomography
- RECIST:
-
Response evaluation criteria in solid tumours
- ULN:
-
Upper limit of normal
References
Hodi FS, O’Day SJ, McDermott DF et al (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320–330
Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372:2521–2532
Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23–34
Long GV, Stroyakovskiy D, Gogas H et al (2015) Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386:444–451
Lebbe C, Weber JS, Maio M et al (2014) Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. Ann Oncol 25:2277–2284
Horvat TZ, Adel NG, Dang TO et al (2015) Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. J Clin Oncol 33:3193–3198
Larkin J, Chiarion-Sileni V, Gonzalez R et al (2015) 3303 Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naïve patients with advanced melanoma (MEL) (CheckMate 067). Eur Cancer Congr 51(Suppl S3):S664–S665. doi:10.1016/S0959-8049(16)31822-6
Wolchok JD, Kluger H, Callahan MK et al (2013) Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 369:122–133
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
James Larkin is a non-remunerated consultant for Novartis, Pfizer, Bristol Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Roche/Genentech, Glasko Smith Kline (GSK) and Eisai and receives institutional research support from Pfizer, BMS, Novartis and MSD. James Larkin and Martin Gore are supported by the National Institute for Health Research Royal Marsden Hospital and Institute of Cancer Research Biomedical Research Centre (NIHR RMH/ICR BRC). Samra Turajlic is a Cancer Research UK (CRUK) Clinician Scientist and is funded by CRUK (Grant Ref. C50947/A18176) and the NIHR RMH/ICR BRC (Grant Ref. A109). The remaining authors have declared no conflicts of interest.
Informed consent
We are very grateful to our patients who gave consent for their clinical details to be included in this paper.
Rights and permissions
About this article
Cite this article
Spain, L., Walls, G., Messiou, C. et al. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer Immunol Immunother 66, 113–117 (2017). https://doi.org/10.1007/s00262-016-1926-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-016-1926-2